Gladstone Institutional Advisory LLC Bristol Myers Squibb CO Transaction History

Gladstone Institutional Advisory LLC

  • $1.81 Billion
  • Q1 2024

A detailed history of Gladstone Institutional Advisory LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gladstone Institutional Advisory LLC holds 101,119 shares of BMY stock, worth $4.09 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
101,119
Previous 62,786 61.05%
Holding current value
$4.09 Million
Previous $3.22 Million 70.23%
% of portfolio
0.3%
Previous 0.18%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$47.98 - $54.4 $1.84 Million - $2.09 Million
38,333 Added 61.05%
101,119 $5.48 Million
Q4 2023

Feb 09, 2024
BUY
$48.48 - $57.85 $502,883 - $600,078
10,373 Added 19.79%
62,786 $3.22 Million
Q3 2023

Nov 13, 2023
BUY
$57.89 - $64.73 $152,598 - $170,628
2,636 Added 5.3%
52,413 $3.04 Million
Q2 2023

Aug 10, 2023
BUY
$63.71 - $70.74 $37,334 - $41,453
586 Added 1.19%
49,777 $3.18 Million
Q1 2023

May 12, 2023
SELL
$65.71 - $74.53 $253,574 - $287,611
-3,859 Reduced 7.27%
49,191 $3.41 Million
Q4 2022

Feb 01, 2023
SELL
$68.48 - $81.09 $1.42 Million - $1.68 Million
-20,773 Reduced 28.14%
53,050 $3.82 Million
Q3 2022

Jan 27, 2023
BUY
$0.13 - $76.84 $3,696 - $2.18 Million
28,433 Added 62.64%
73,823 $5.25 Million
Q3 2022

Oct 20, 2022
BUY
$0.13 - $76.84 $3,696 - $2.18 Million
28,433 Added 62.64%
73,823 $5.25 Million
Q2 2022

Jan 27, 2023
SELL
$72.62 - $79.98 $170,947 - $188,272
-2,354 Reduced 4.93%
45,390 $3.5 Million
Q2 2022

Aug 15, 2022
SELL
$72.62 - $79.98 $170,947 - $188,272
-2,354 Reduced 4.93%
45,390 $3.5 Million
Q1 2022

Jan 27, 2023
SELL
$61.48 - $73.72 $5,656 - $6,782
-92 Reduced 0.19%
47,744 $3.49 Million
Q1 2022

May 04, 2022
SELL
$61.48 - $73.72 $5,656 - $6,782
-92 Reduced 0.19%
47,744 $3.49 Million
Q4 2021

Jan 27, 2023
BUY
$53.63 - $62.52 $613,580 - $715,291
11,441 Added 31.44%
47,836 $2.98 Million
Q4 2021

Feb 11, 2022
BUY
$53.63 - $62.52 $613,580 - $715,291
11,441 Added 31.44%
47,836 $2.98 Million
Q3 2021

Jan 27, 2023
SELL
$59.17 - $69.31 $58,341 - $68,339
-986 Reduced 2.64%
36,395 $2.15 Million
Q3 2021

Nov 15, 2021
SELL
$59.17 - $69.31 $58,341 - $68,339
-986 Reduced 2.64%
36,395 $2.15 Million
Q2 2021

Jan 27, 2023
BUY
$61.91 - $67.42 $295,682 - $321,997
4,776 Added 14.65%
37,381 $2.5 Million
Q2 2021

Aug 13, 2021
BUY
$61.91 - $67.42 $295,682 - $321,997
4,776 Added 14.65%
37,381 $2.5 Million
Q1 2021

Jan 27, 2023
BUY
$59.34 - $66.74 $140,398 - $157,906
2,366 Added 7.82%
32,605 $2.06 Million
Q1 2021

May 17, 2021
BUY
$59.34 - $66.74 $140,398 - $157,906
2,366 Added 7.82%
32,605 $2.06 Million
Q4 2020

Jan 27, 2023
SELL
$57.74 - $65.43 $521,103 - $590,505
-9,025 Reduced 22.99%
30,239 $1.88 Million
Q4 2020

Feb 16, 2021
SELL
$57.74 - $65.43 $521,103 - $590,505
-9,025 Reduced 22.99%
30,239 $1.88 Million
Q3 2020

Jan 27, 2023
SELL
$57.43 - $63.64 $1.98 Million - $2.2 Million
-34,559 Reduced 46.81%
39,264 $2.37 Million
Q3 2020

Nov 16, 2020
SELL
$57.43 - $63.64 $21,880 - $24,246
-381 Reduced 0.96%
39,264 $2.37 Million
Q2 2020

Aug 17, 2020
SELL
$54.82 - $64.09 $79,489 - $92,930
-1,450 Reduced 3.53%
39,645 $2.33 Million
Q1 2020

May 14, 2020
BUY
$46.4 - $67.43 $2,180 - $3,169
47 Added 0.11%
41,095 $2.29 Million
Q4 2019

Feb 12, 2020
BUY
$49.21 - $64.19 $237,635 - $309,973
4,829 Added 13.33%
41,048 $2.64 Million
Q3 2019

Nov 13, 2019
BUY
$42.77 - $50.71 $1.55 Million - $1.84 Million
36,219 New
36,219 $1.84 Million

Others Institutions Holding BMY

# of Institutions
2,553
Shares Held
1.49B
Call Options Held
25.9M
Put Options Held
20M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $86B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Gladstone Institutional Advisory LLC Portfolio

Follow Gladstone Institutional Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gladstone Institutional Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gladstone Institutional Advisory LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email